COLORADO ODS EXPAND THEIR AUTHORITY
Another state allows optometrists to perform many office-based surgical procedures, including laser procedures.
BY RENÉ LUTHE, SENIOR EDITOR
In a continuing nationwide trend, Colorado granted optometrists expanded scope of practice, including laser procedures. H.B. 22-1233 gives ODs authority to perform certain office-based procedures including:
- Injections for treating conditions or diseases of the eye or eyelid (excluding intraocular injections penetrating the globe)
- Removal and biopsy of eyelid lesions without characteristics or obvious signs of malignancy (excluding lesions involving the eyelid margin or larger than 5 mm)
- Incision and curettage of a chalazion
- Simple repair of an eyelid laceration no larger than 2.5 cm and no deeper than the orbicularis muscle and not involving the eyelid margin or lacrimal drainage structures
- Corneal cross-linking
- Laser capsulotomy, laser peripheral iridotomy and laser trabeculoplasty
The legislation makes Colorado the 10th state to expand optometric authority and the fourth since 2021.
While they respect and appreciate the contributions of ODs they work with, many ophthalmologists remain concerned about the ongoing expansion, says Richard S. Davidson, MD, professor and vice chair for quality and clinical affairs, cataract, cornea and refractive surgery at University of Colorado Sue Anschutz-Rodgers Eye Center and University of Colorado School of Medicine, Aurora.
“I am very proud of the optometrists in our group and the many optometrists I have worked with over the past 20 years of my career,” he says. “That being said, I think the optometry lobby has over-simplified the procedures for which they are now approved, all of which can come with significant complications for the patient.”
Dr. Davidson notes that for him to be approved to perform the same procedures, he was required to complete 4 years of training to become an MD, a 1-year general medicine internship and a minimum 3 years of residency training. “The requirement of the 3-year residency is to allow one to do many of these cases hundreds of times in order to be deemed competent to perform the procedure. Just being ‘taught’ about the procedures or perhaps doing a wet lab during optometry school does not make one competent to perform the procedure. In fact, it leaves the public at high risk for significant ocular complications without them knowing just how at risk they are because these procedures have been ‘approved’ by the legislature.” OM
SURVEY REVEALS BURNOUT AMONG OPHTHALMOLOGISTS
Results reveal higher rates in women and those in academic and hospital settings.
BY ZACK TERTEL, MANAGING EDITOR
A recent survey of US ophthalmologists revealed self-reported burnout. Published in the June 2022 issue of Journal of Cataract & Refractive Surgery, the results showed that 37.8% of respondents (224 of 592 ophthalmologists) have symptoms of burnout.1 These numbers were highest among uveitis specialists (30 of 66, or 45.4%). Women had nearly twice the odds of reporting burnout, and those employed in academic and hospital facilities reported higher rates of burnout compared with those in large private groups.
Fortunately, most of those reporting burnout (65.2%) were categorized as mild, followed by 29.5% at moderate levels and 5.4% at severe. According to the study by Sedhom et al, “Burnout was associated with self-reported low work control, insufficient time for documentation and misalignment with departmental leaders.”
A 2020 survey that included more occupations uncovered similar burnout rates in ophthalmology (30%). Though ophthalmology was among the least burned-out specialties in the survey, reported rates were higher than nonphysicians.2 Another study from 2018 of US ophthalmology residents showed burnout symptoms in as many as 63% of respondents.3
For Blake K. Williamson, MD, MPH, MS, of Williamson Eye Center in Louisiana, the burnout is the result of a variety of influences. “On a very simple level, the reason why is that surgeons are being asked to do more surgery for less money for patients who expect more while using staff who are harder to find and harder to keep.”
With so many contributing factors, solutions to avoiding burnout are far from simple. Still, small changes can make a significant difference. For example, along with adding yoga and meditation to his weekly routine, Dr. Williamson recently opted to no longer see patients on Fridays. “That will be my day to do more administrative tasks, speak to my management team and work on my business rather than work in my business.” OM
TIPS ON RESILIENCE DEVELOPMENT AND BURNOUT PREVENTION*
- Recognize the indicators
- Bolster your resilience
- Understand and accept reality
- Become non-defensive
- Become mindfully present
- Walk to the beat of your own drum
- Look internally for joy
- Strengthen your social connections
- Become optimistic
- Count your blessings with gratitude
- Find a purpose greater than yourself
*From December 2021 OM article “How can I overcome burnout?” by James D. Dawes, MHA, CMPE, COE, and Craig N. Piso, PHD. For more, see bit.ly/omburnout .
REFERENCES
- Sedhom JA, Patnaik JL, McCourt EA, et al. Physician burnout in ophthalmology: U.S. survey. J Cataract Refract Surg. 2022;48(6):723-729.
- Kane L. Medscape National Physician Burnout & Suicide Report 2020: The Generational Divide. Medscape. 2020.
- Feng S, Taravati P, Ding L, Menda S. Burnout in ophthalmology residency: a national survey. J Acad Ophthalmol. 2018;10:e98-e107.
IN THE NEWS:
Aetna will no longer require prior authorization for cataract surgery, except for Medicare Advantage beneficiaries in Florida and Georgia. In a press release, ASCRS President Douglas Rhee, MD, said he is “thrilled about the work that was done over the past year by ASCRS and AAO that led to Aetna dropping its prior authorization policy for cataract surgery.”
The U.S. Centers for Medicare and Medicaid Services issued a permanent, product-specific J-Code J3299 “Injection, Triamcinolone acetonide (XIPERE) 1 mg” for Bausch + Lomb’s XIPERE (triamcinolone acetonide injectable suspension), which became effective for provider billing on July 1, 2022. J-Codes are reimbursement codes used by both commercial insurers and government payers to quickly identify therapies that are administered by a health-care professional incident to the office visit.
LENSAR announced FDA 510(k) clearance for its next-generation ALLY Adaptive Cataract Treatment System. ALLY is the first FDA-cleared platform to enable cataract surgeons to complete the femtosecond laser-assisted cataract surgery procedure in a single, sterile environment. LENSAR plans to deliver the first ALLY Systems to surgeons in the third quarter of this year then make ALLY widely available to cataract surgeons in 2023.
The FDA granted Olympic Ophthalmics’ 510(K) request for its second-generation iTEAR100 device, a prescription neuromodulation therapy to acutely increase tear production in adult patients over a 30-day period. The connected device offers telehealth tools, including prescription download capability and activation through a mobile phone app. The company also announced three ongoing trials to support its broad label “increasing tear production in adult patients” and its treatment paradigm.
Harrow Health completed the transfer to Harrow of the new drug applications of recently acquired, FDA-approved ophthalmic medicines: IOPIDINE 1%, MAXITROL 3.5mg/10,000 units/0.1% and MOXEZA 0.5%. In addition, IOPIDINE 1% and MAXITROL are now commercially available; Harrow intends to commercialize MOXEZA 0.5% at a later date. Product orders for IOPIDINE 1% and MAXITROL can be made directly through Harrow’s partner, Cardinal’s Cordlogistics.
In Aldeyra Therapeutics’ Phase 3 TRANQUILITY-2 clinical trial, reproxalap, an investigational new drug candidate for dry eye disease, reached its primary endpoint. Reproxalap was statistically superior to vehicle for each of the two prespecified primary endpoints, Schirmer test (p=0.0001) and ≥10 mm Schirmer test responder proportions (p<0.0001) after a single day of dosing. Aldeyra intends to submit an NDA with ocular dryness symptom score, ocular redness, Schirmer test and ≥10 mm Schirmer test responder analysis, encompassing results across five adequate and well-controlled completed clinical trials.